Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation

Chimerism

Volumn 3, Issue 2, 2012, Pages

  Kornblit, Brian ^a   Chen, Yun ^a   Sandmaier, Brenda M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic transplant; Alpha emitter; Chimerism; Nonmyeloablative; Radioimmunotherapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; ASTATINE MONOCLONAL ANTIBODY CD45 AT 211; BISMUTH 213; BISMUTH MONOCLONAL ANTIBODY CD45 BI 213; BISMUTH MONOCLONAL ANTIBODY TCR ALPHA BETA BI 213; LEUKOCYTE ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG; BISMUTH; CD45 ANTIGEN; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALPHA RADIATION; ARTICLE; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EXPERIMENTAL DOG; NONHUMAN; NONMYELOABLATIVE CONDITIONING; RADIATION CHIMERA; RADIATION DOSE; RADIATION RESPONSE; RADIATION SAFETY; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; ALLOTRANSPLANTATION; ANIMAL; CHEMISTRY; DOG; GRAFT REJECTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; NATURAL KILLER CELL;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BISMUTH; DOGS; GRAFT REJECTION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KILLER CELLS, NATURAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84863661878     PISSN: 19381956     EISSN: 19381964     Source Type: Journal    
DOI: 10.4161/chim.20726     Document Type: Article

References (27)

1. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390-400; PMID:11369628; http://dx.doi.org/10.1182/blood.V97.11.3390
2. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLAmatched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-9; PMID:12393457; http://dx.doi.org/10.1182/blood-2002-05-1340
3. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54:829-33; PMID: 1440849; http://dx.doi.org/10.1097/00007890-199211000-00012
4. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001; 98:565-72; PMID:11468151; http://dx.doi.org/10.1182/blood.V98.3.565
5. Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114:5444-53; PMID: 19786617; http://dx.doi.org/10.1182/blood-2009-03-213298
6. Schulz AS, Glatting G, Hoenig M, Schuetz C, Gatz SA, Grewendorf S, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 2011; 117:4642-50; PMID:21325170; http://dx.doi.org/10.1182/blood-2010-06-284349
7. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody, Immunoconjugates, and Radiopharmaceuticals 1991; 4:85-97.
8. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res 1991; 128:204-9; PMID:1947017; http://dx.doi.org/10.2307/3578139
9. Dadachova E. Cancer therapy with alpha-emitters labeled peptides. [Review] [Erratum appears in Semin Nucl Med. 2010 Jul;40(4):219]. Semin Nucl Med 2010; 40:204-8; PMID:20350629; http://dx.doi.org/10.1053/j.semnuclmed.2010.01.002
10. Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, et al. Radiotoxicity of bismuth- 213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 1999; 151:244-56; PMID:10073661; http://dx.doi.org/10.2307/3579935
11. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980; 152:842-52; PMID:6968338; http://dx.doi.org/10.1084/jem.152.4.842
12. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983; 79:546-52; PMID:6188365
13. Nakamura H, Gress RE. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation 1990; 49:453-8; PMID:2305471; http://dx.doi.org/10.1097/00007890-199002000-00042
14. Kikly K, Dennert G. Evidence for a role for T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. TCR V beta 5 transgenic mice lack effector cells able to cause graft rejection. J Immunol 1992; 149:3489-94; PMID:1431119
15. Raff RF, Sandmaier BM, Graham T, Loughran TP, Jr., Pettinger M, Storb R. "Resistance" to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 1994; 22:893-7; PMID:8062888
16. Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100:318-26; PMID:12070043; http://dx.doi.org/10.1182/blood-2001-12-0322
17. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, et al. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 2004; 78: 352-9; PMID:15316362; http://dx.doi.org/10.1097/01.TP.0000128853.62545.B2
18. Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the a-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009; 69:2408-15; PMID:19244101; http://dx.doi.org/10.1158/0008-5472.CAN-08-4363
19. Wilbur DS, Chyan M-K, Nakamae H, Chen Y, Hamlin DK, Santos EB, et al. Reagents for astatination of Biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjug Chem 2012; 23:409-20; PMID:22296587; http://dx.doi.org/10.1021/bc200401b
20. Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, et al. Durable donor engraftment after radioimmunotherapy using a-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012; 119:1130-8; PMID:22134165; http://dx.doi.org/10.1182/blood-2011-09-380436
21. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3048-54; PMID:9108426
22. Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy 2011; 13: 1269-80; PMID:21846291; http://dx.doi.org/10.3109/14653249.2011.586997
23. Nakamae H, Kerbauy FR, Wilbur DS, Bethge W, Hamlin DK, Santos EB, et al. Pilot study of a (213) bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation 2010; 89:1336-40; PMID:20351629; http://dx.doi.org/10.1097/TP.0b013e3181d98c3d
24. Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002; 73:1487-92; PMID:12023629; http://dx.doi.org/10.1097/00007890-200205150-00020
25. Mathes DW, Hwang B, Graves SS, Edwards J, Chang J, Storer BE, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation 2011; 92:1301-8; PMID:22082819; http://dx.doi.org/10.1097/TP.0b013e318237d6d4
26. Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: Principles and prospects in oncology. Current Pharmceutical Design 2012; In press
27. Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Pötter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002; 29:842-54; PMID:12111124; http://dx.doi.org/10.1007/s00259-002-0784-7